Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To describe a cohort of patients with AdvSM treated with midostaurin according to local label and a cohort of patients with AdvSM non treated with midostaurin in clinical practice, to fill the knowledge gap between the clinical experience from registration trials and routine patient's management in Italy

Next Previous
Trial Profile

To describe a cohort of patients with AdvSM treated with midostaurin according to local label and a cohort of patients with AdvSM non treated with midostaurin in clinical practice, to fill the knowledge gap between the clinical experience from registration trials and routine patient's management in Italy

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Midostaurin (Primary)
  • Indications Systemic mastocytosis
  • Focus Therapeutic Use
  • Acronyms OVIDIO

Most Recent Events

  • 13 Dec 2022 Interim Results (At data cut-off Jan 31, 2022, n=66) of patients in the MT cohort who completed 12 months of follow-up or discontinued treatment within 12 months, presented at the 64th American Society of Hematology Annual Meeting and Exposition
  • 12 Aug 2022 New trial record
  • 17 Jun 2022 As of February 2022, 64 and 18 patients have been enrolled in the midostaurin treated and not treated cohort respectively. Enrollment is ongoing.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top